Literature DB >> 9154766

Measurements of serum müllerian inhibiting substance in the evaluation of children with nonpalpable gonads.

M M Lee1, P K Donahoe, B L Silverman, T Hasegawa, Y Hasegawa, M L Gustafson, Y C Chang, D T MacLaughlin.   

Abstract

BACKGROUND: Müllerian inhibiting substance, produced constitutively by the prepubertal testes, promotes involution of the müllerian ducts during normal male sexual differentiation. In children with virilization and nonpalpable gonads, only those with testicular tissue should have detectable serum concentrations of müllerian inhibiting substance.
METHODS: We measured serum mullerian inhibiting substance in 65 children with virilization at birth and nonpalpable gonads (age at diagnosis, 2 days to 11 years) and serum testosterone in 54 of them either after the administration of human chorionic gonadotropin or during the physiologic rise in testosterone that occurs in normal infants.
RESULTS: The mean (+/-SD) serum mullerian inhibiting substance concentration in the 17 children with no testicular tissue was 0.7+/-0.5 ng per milliliter, as compared with 37.5+/-39.6 ng per milliliter in the 48 children with testes (P<0.001). In the latter group, the mean values in the 14 children with abnormal testes and the 34 with normal testes were 11.5+/-11.8 and 48.2+/-42.1 ng per milliliter, respectively (P< 0.001). The sensitivity and specificity of the serum müllerian inhibiting substance assay for detecting the absence of testicular tissue were 92 percent and 98 percent, respectively, as compared with 69 percent and 83 percent for the measurement of serum testosterone. Furthermore, measurement of serum mullerian inhibiting substance was more sensitive than serum testosterone measurement for the identification of children with abnormal testes (67 percent vs. 25 percent), whereas the specificity of the two tests was similar.
CONCLUSIONS: Measurements of serum mullerian inhibiting substance can be used to determine testicular status in prepubertal children with nonpalpable gonads, thus differentiating anorchia from undescended testes in boys with bilateral cryptorchidism and serving as a measure of testicular integrity in children with intersexual anomalies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9154766     DOI: 10.1056/NEJM199705223362102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  28 in total

1.  Diagnosis and medical-surgical treatment of cryptorchidism.

Authors:  C de Sanctis; R Lala
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

2.  Canadian Urological Association-Pediatric Urologists of Canada (CUA-PUC) guideline for the diagnosis, management, and followup of cryptorchidism.

Authors:  Luis H Braga; Armando J Lorenzo; Rodrigo L P Romao
Journal:  Can Urol Assoc J       Date:  2017-07-11       Impact factor: 1.862

3.  AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy.

Authors:  Motohiro Kano; Amanda E Sosulski; LiHua Zhang; Hatice D Saatcioglu; Dan Wang; Nicholas Nagykery; Mary E Sabatini; Guangping Gao; Patricia K Donahoe; David Pépin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

Review 4.  Evaluation of testicular function in prepubertal children.

Authors:  Rosita A Condorelli; Rossella Cannarella; Aldo E Calogero; Sandro La Vignera
Journal:  Endocrine       Date:  2018-07-07       Impact factor: 3.633

Review 5.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

6.  Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development.

Authors:  Kahina Boukari; Geri Meduri; Sylvie Brailly-Tabard; Jean Guibourdenche; Maria Luisa Ciampi; Nathalie Massin; Laetitia Martinerie; Jean-Yves Picard; Rodolfo Rey; Marc Lombès; Jacques Young
Journal:  J Clin Endocrinol Metab       Date:  2009-03-10       Impact factor: 5.958

Review 7.  The undescended testis: diagnosis, treatment and long-term consequences.

Authors:  Michael J Mathers; Herbert Sperling; Herbert Rübben; Stephan Roth
Journal:  Dtsch Arztebl Int       Date:  2009-08-14       Impact factor: 5.594

8.  Mutational analysis of steroidogenic factor 1 (NR5a1) in 24 boys with bilateral anorchia: a French collaborative study.

Authors:  Pascal Philibert; Delphine Zenaty; Lin Lin; Sylvie Soskin; Françoise Audran; Juliane Léger; John C Achermann; Charles Sultan
Journal:  Hum Reprod       Date:  2007-10-16       Impact factor: 6.918

9.  AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.

Authors:  David Pépin; Amanda Sosulski; Lihua Zhang; Dan Wang; Vinod Vathipadiekal; Katherine Hendren; Caroline M Coletti; Aaron Yu; Cesar M Castro; Michael J Birrer; Guangping Gao; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

10.  The effects of orchiopexy on serum anti-Müllerian hormone levels in unilateral cryptorchid infants.

Authors:  Mehmet Demircan; Aysehan Akinci; Murat Mutus
Journal:  Pediatr Surg Int       Date:  2006-02-04       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.